{"analyses":[{"ciLowerLimit":"0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.1","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.1222","paramType":"Hazard Ratio (HR)","paramValue":"0.7","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit not calculated due to insufficient number of events.","groupId":"OG000","lowerLimit":"439.4","upperLimit":"NA","value":"NA"},{"comment":"Median and upper limit not calculated due to insufficient number of events.","groupId":"OG001","lowerLimit":"395.7","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time between the first dose date of maintenance therapy and death from any cause. Participants who complete the study and are still alive at the time of the clinical data cutoff date will be censored at the last visit date or the last contact date, whichever is later. Participants who were lost to follow-up prior to the clinical data cut-off date will also be censored at the time of the last contact. Analysis was based on Kaplan Meier estimates and Hazard Ratio (HR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and Arm B, as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy to death from any cause (up to approximately 480 weeks)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Weeks"}